Long-term use of a left ventricular assist device for end-stage heart failure.

By E. A. Rose, A. Gelijns, Alan J. Moskowitz, Daniel F. Heitjan, L. Stevenson, Walter Dembitsky, J. Long, D. Ascheim, A. Tierney, Ronald G. Levitan and 11 more. New England Journal of Medicine, 2001

3,630 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Surgery

View Paper: https://www.semanticscholar.org/paper/d3c92939c2d2b42ceb6e954709aaaa41c2103e14

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. B. Bozkurt
2. P. Ponikowski
3. M. Jessup
4. J. McMurray
5. P. Seferovic
6. A. Voors
7. N. K. Lakdawala
8. Helmut Baumgartner

Citations in the corpus

• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “this approach (281-285), it becomes reasonable to recommend viability assessment when treating patients with”
• On the biomechanics of heart valve function. (2009, background): “Left ventricular assist device (LVAD) is a pump surgically connected to the heart and aorta in order to boost systemic blood flow (Rose et al., 2001).”
• Dilated Cardiomyopathy (2007, positive): “This MCS, historically used only for short periods as bridge-totransplantation, nowadays is being used increasingly also as a permanent treatment or “destination therapy” [75].”
• Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. (2009, methodology): “Although demonstrating the potential of CS in providing improved survival, this trial demontrated the risk of mechanical failure and device-related omplications inherent in the pulsatile HeartMate VE VAD (3,12).”